05:26:02 EST Tue 18 Dec 2018
Enter Symbol
or Name
USA
CA



FSD Pharma Inc
Symbol C : HUGE
Shares Issued 1,372,586,671
Close 2018-12-04 C$ 0.33
Recent Sedar Documents

FSD Pharma congratulates Canntab on partnership

2018-12-05 13:20 ET - News Release

Mr. Zeeshan Saeed reports

FSD PHARMA CONGRATULATES PARTNER CANNTAB ON LAUNCH OF RESEARCH PARTNERSHIP WITH LEADING ORTHOPAEDIC SURGEON DR. DON GARBUZ, M.D.

FSD Pharma Inc. has congratulated its strategic partner, Canntab Therapeutics Ltd., on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, doctor of medicine. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia, subject to the university's approval, that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab's sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ont., with FSD Pharma in furtherance of their collaboration and licence agreement, dated Sept. 17, 2018.

About FSD Pharma Inc.

FSD Pharma is focused on the development of the highest-quality indoor-grown, pharmaceutical-grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The company's phase one growth plan involves the development of 25,000 square feet of indoor grow space at its Ontario facility and an additional 220,000 square feet, which pending approval by Health Canada, is expected to be operational in the first quarter 2019. FSD Pharma's facilities sit on 72 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.